News About Expanesthetics

Expanesthetics Passes $2.25M Fundraising Hurdle

February 17, 2017

On its way to accelerating development of its analgesic and anesthetic programs, Expanesthetics announces the completion of an important fundraising target: $2.25M in seed funding. "This is just the start to a major multi-year campaign to bring brand new approaches to both general anesthesia and pain," said CEO Mark Holman. Holman continued, "The dozens of anesthesiologists who are participating investors in our company shows the market demand for major changes and the potential of our technology to meet that need."

Back to top

Expanesthetics Exhibits at 55th Clinical Conference in Pediatric Anesthesiology

February 6, 2017

This month, for the third year in a row, Expanesthetics is sponsoring and exhibiting at the Annual Clinical Conference in Pediatric Anesthesiology in Anaheim, California. This yearly sponsorship is an important annual tradition as Expanesthetics continues to develop relationships with the pediatric anesthesia community. Following the success of the survey conducted at the American Society of Anesthesiologists 2016 Annual Meeting in Chicago (ASA), Expanesthetics is conducting a follow-on survey during this pediatric conference to explore any variations in the responses of the pediatric anesthesia community when compared to the broader anesthesia community at large. Please contact us directly if you are interested in the results of this follow-on survey, or the original survey upon which it was based.

Back to top

Expanesthetics Exhibits at American Society of Anesthesiologists 2016 Annual Meeting in Chicago

October 31, 2016

Expanesthetics exhibited this month for the second time at the American Society of Anesthesiologists 2016 Annual Meeting in Chicago (ASA). ASA provided the Expanesthetics team an opportunity to advance conversations with an enormous range of potential partners, including potential production, synthesis, device and distribution partners from China, South Korea, Japan, Europe and the U.S. On the convention floor this year, Expanesthetics also continued to solicit input from the anesthesiologist community on the development of a new inhalation general anesthetic through a newly designed participant survey. The survey focused on the value of improving hemodynamic stability in patients, and sought to determine the likelihood of adoption of a proposed new anesthetic. It also explored what side effects the respondent would be willing to trade off for a non-hypotensive anesthetic compared with the currently preferred agent. By the end of the conference, over 250 participants had taken the survey. Please contact us directly if you are interested in learning about the results.

Back to top